The identification of individuals at risk for Alzheimer's disease (AD) is essential for the timely administration of treatment approaches aimed at slowing the onset or progression of the disease. As amnestic forms of mild cognitive impairment (aMCI) may represent preclinical AD, the search for specific diagnostic biomarkers that characterize those with aMCI is a key research objective. Using surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDITOF-MS), we screened the cerebrospinal fluid (CSF) of Religious Orders Study participants with a clinical diagnosis of no cognitive impairment (NCI), aMCI, or mild/moderate AD for potential biomarkers. CSF was fractionated on immobilized metal affinity chromatography (IMAC) protein arrays preloaded with either gallium (IMAC-Ga), which binds phosphoproteins, or copper (IMAC-Cu) to isolate copperbinding proteins. SELDI TOF-MS analysis of the IMAC-Ga arrays revealed a phosphopeptide of 2490 Da that was selectively increased ~2-fold in aMCI and AD CSF compared to NCI. SELDI TOF-MS analysis of the IMAC-Cu arrays identified 2 proteins of 11.7 and 13.3 kDa that were both selectively increased ~1.5-1.6-fold in aMCI and AD CSF. Increasing levels of each protein were associated with poorer performance on the Mini Mental State Exam and higher Braak stage. Hence, increased CSF levels of these proteins may be potential biomarkers for preclinical AD and aid in the development of a CSF biomarker panel with high predictive value for identifying people who would most benefit from early therapeutic interventions to modify disease progression.
introduction
Alzheimer's disease (AD) is currently defiined by its characteristic clinical manifestation of dementia.
Since neuropathological examination of older people with a clinical diagnosis of no or mild cognitive impairment (MCI), a putative preclinical stage of AD [1] , consistently reveal similar pathological signatures to those with frank AD [2] [3] [4] [5] [6] , it is now suggested that the disease begins many years before the onset of clinical symptoms. Therefore, the ability to identify at-risk people prior to cognitive decline is a key objective for clinicians as well as for gauging the long-term therapeutic effects of AD modifying drugs.
In this regard, several initiatives have been launched to understand whether a panel of diagnostic and prognostic biomarkers can be developed which characterize people at the earliest stages of the disease, particularly those with amnestic MCI (aMCI) who preferentially transition to AD [1] . Current studies have focused on detecting biomarkers associated with changes in amyloid-β (Aβ) peptide and tau protein levels in the cerebrospinal fluid (CSF) of people at varying stages of AD, since these markers may reflect underlying cerebral pathology [7] . In particular, studies have
shown that the CSF of AD patients contains decreased levels of Aβ 42 peptides, which form the nidus of amyloid plaques, and elevated levels of tau or phosphorylated tau, the principle constituent of neurofibrillary tangles (NFTs) [8] [9] [10] [11] . In general, changes in the ratio of Aβ 42 and tau or phospho-tau levels are predictive for longitudinal changes in cognitive measures [12] [13] [14] [15] [16] . However, the inherent variability and overlap of AD neuropathology in the aged control, MCI and diseased brain is also reflected by variation of these targets in the CSF, resulting in suboptimal specificity and sensitivity for identifying subjects in were not cognitively normal, but did not meet accepted criteria for dementia [1] . The MCI population is defined as those persons rated as impaired on neuropsychological testing by the neuropsychologist but who were not found to have dementia by the examining neurologist [3, 17] . Subjects in the MCI diagnostic group are subclassified as amnestic (aMCI) or nonamnestic based on the presence or absence of impairments in episodic memory, respectively.
experimental Procedures
This differentiation is established to allow for studies focused on the aMCI subtype, which may be more representative of prodromal AD [1, 19] . As such, CSF from aMCI subjects was used for these studies. Postmortem interviews were carried out to determine medical conditions which occurred during the interval between the last clinical evaluation and death. A consensus conference of neurologists and neuropsychologists reviewed all available clinical data, and assigned a summary clinical diagnosis.
Pathological Evaluation
At autopsy, brains were processed as previously described [3, 20] . Brains were removed from the calvarium, cut into 1-cm thick slabs using Reagan, and CERAD diagnosis) for each subject.
Statistical significance was set at p < 0.05.
results

Case demographics
The three clinical groups were comparable in age, education, and PMI ( 
SELDITOF-MS analysis ofIMAC-Ga CSFprotein arrays
CSF samples were first incubated with the IMAC-Ga protein arrays to enrich for phosphoproteins which might be altered in aMCI and/or AD. SELDI TOF-MS spectra from these arrays demonstrated that most CSF phosphopeptide peaks were concentrated in the 2000 -8000 Da range (Fig. 1 A) . Focusing the spectra into the 2200-2800 Da range revealed an increase of a ~2490 Da phosphopeptide in the CSF of aMCI and AD subjects relative to NCI (Fig. 1B) . Quantitative analysis indicated that the peak intensity of the CSF 2490 Da phosphopeptide was increased ~2-fold in aMCI
and AD compared to NCI subjects (Fig. 1C) . The increase in CSF levels of the 2490 Da peptide was correlated with poorer cognitive scores ( Fig. 2A, Table 2 ). CSF levels of the 2490 Da peptide correlated with the Braak tangle score but not with NIA Reagan or CERAD criteria (Table 2) . Significantly, there was no association Translational Neuroscience between phosphopeptide levels and PMI (Fig. 2B, Table 2) , indicating the protein level changes were unrelated to autolysis.
SELDI TOF-MS analysis CSF protein arrays
We also tested whether CSF samples could be enriched for differentially expressed Cu 2+ -binding proteins using the IMAC-Cu protein array. SELDI TOF-MS spectra from IMAC-Cu arrays showed a broad spectrum of protein peaks between 1500 and 15000 Da (Fig. 3A) . Two protein peaks of ~11.7 kDa and ~13.3 kDa appeared increased in the CSF of aMCI and AD relative to NCI subjects (Fig. 3B ). Quantitative analysis of the spectra indicated that both of the Cu 2+ -binding proteins were increased ~1.5-1.6-fold in the CSF of aMCI and AD cases compared to the NCI group (Fig. 3C ). Similar to the phosphopeptide, higher CSF levels of the 11.7 and 13.3 kDa proteins were inversely correlated with lower MMSE cognitive scores and correlated with Braak but not NIA Reagan or CERAD neuropathologic scores.
Protein levels were not associated with PMI (Table 2 ).
discussion
In this report we demonstrate the utility of Translational Neuroscience factor [24, 25] , apolipoprotein isoforms [25, 26] , prostaglandin-d-synthase:transthyretin dimers [27] , and potentially synuclein isoforms [28] and ubiquitin [29, 30] Table 2 . Spearman correlations between CSF proteins and clinical pathologic variables Fig. 3 Two copper-binding proteins of 11.7 and 13.3 kDa are increased in the CSF of aMCI and AD subjects.
A) Representative SELDI TOF spectra from IMAC-Cu arrays identify a wide array of CSF peptides and proteins in the 2000 Da to 15 kDa range. Individual spectra are normalized to total ion current. B) Inspection of the spectra show potential differences in the peak intensities of two proteins with predicted masses of 11.7 kDa and 13.3 kDa among NCI, aMCI and AD CSF samples C,D) Bar graph shows that levels of the 11.7 kDa protein (C) and the 13.3 kDa protein (D) are increased ~1.5-1.6-fold increase in the CSF of aMCI and AD subjects compared to NCI. 
